Twist Bioscience (NASDAQ:TWST) Price Target Raised to $55.00

Twist Bioscience (NASDAQ:TWST) had its price objective raised by The Goldman Sachs Group from $45.00 to $55.00 in a research note released on Tuesday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other analysts also recently weighed in on the company. Evercore ISI lifted their target price on Twist Bioscience from $46.00 to $50.00 and gave the company an outperform rating in a research note on Friday, May 3rd. TD Cowen lifted their target price on Twist Bioscience from $55.00 to $65.00 and gave the company a buy rating in a research note on Thursday, June 13th. Barclays lifted their price target on Twist Bioscience from $45.00 to $60.00 and gave the company an overweight rating in a research report on Friday, June 28th. Scotiabank boosted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the stock a sector outperform rating in a research note on Monday, May 6th. Finally, Guggenheim assumed coverage on Twist Bioscience in a research note on Tuesday, June 4th. They issued a buy rating and a $53.00 price objective on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and an average price target of $49.75.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $52.48 on Tuesday. Twist Bioscience has a 12-month low of $14.42 and a 12-month high of $55.26. The stock’s 50 day simple moving average is $47.08 and its 200 day simple moving average is $39.20.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The firm’s revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.06) EPS. Sell-side analysts expect that Twist Bioscience will post -3.08 earnings per share for the current year.

Insider Transactions at Twist Bioscience

In other news, COO Patrick John Finn sold 2,174 shares of the business’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the sale, the chief operating officer now directly owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Patrick John Finn sold 2,174 shares of the business’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the sale, the chief operating officer now directly owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider William Banyai sold 798 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $29,629.74. Following the transaction, the insider now directly owns 345,188 shares in the company, valued at $12,816,830.44. The disclosure for this sale can be found here. Insiders have sold 19,570 shares of company stock valued at $827,162 over the last three months. Company insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. ARK Investment Management LLC raised its position in Twist Bioscience by 6.3% during the fourth quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after buying an additional 427,274 shares during the period. Artisan Partners Limited Partnership raised its position in Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after buying an additional 1,961,621 shares during the period. Sumitomo Mitsui Trust Holdings Inc. raised its position in Twist Bioscience by 2.9% during the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after buying an additional 99,511 shares during the period. Nikko Asset Management Americas Inc. grew its stake in Twist Bioscience by 2.9% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after purchasing an additional 99,511 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in Twist Bioscience by 29.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock valued at $46,732,000 after purchasing an additional 284,884 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.